Spinal Muscular Atrophy
Biogen’s Higher Dose Spinraza Shows Enhanced Efficacy in Treating Spinal Muscular Atrophy
Biogen, Spinraza, Nusinersen, Spinal Muscular Atrophy (SMA), Higher Dose Regimen, Clinical Trial Results, DEVOTE Study, Motor Function Improvement, Neurodegeneration Reduction
Scholar Rock Seeks $275M Funding Following Successful SMA Therapy Trial
Scholar Rock, funding, SMA therapy, clinical trial, Vincerx, pipeline reshuffle
Scholar Rock’s Stock Skyrockets 300% Following Successful Phase III Trial of Apitegromab for Spinal Muscular Atrophy
Scholar Rock, Spinal Muscular Atrophy (SMA), Apitegromab, Phase III Trial, Stock Surge, Biologics License Application (BLA), Marketing Authorisation Application (MAA)
Scholar Rock’s Apitegromab Shows Significant Improvement in Spinal Muscular Atrophy Treatment
Spinal Muscular Atrophy (SMA), Apitegromab, Phase 3 Clinical Trial, Motor Function Improvement, Myostatin Inhibition
Voyager Therapeutics Secures $100M Upfront Payment in Expanded Gene Therapy Partnership with Novartis
Gene therapy, Novartis, Voyager Therapeutics, Huntington’s disease, Spinal muscular atrophy (SMA), TRACER capsid discovery platform, Biotechnology collaboration
Biogen Announces Positive Results from Higher Dose Spinraza Study in Spinal Muscular Atrophy Patients
Biogen, Spinraza, spinal muscular atrophy, SMA, higher dose, clinical trial, DEVOTE study